Racial differences in tumor stage and survival for colorectal cancer in an insured population

Department of Family Medicine and Community Health, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Cancer (Impact Factor: 4.9). 02/2007; 109(3):612-20. DOI: 10.1002/cncr.22437
Source: PubMed

ABSTRACT Despite declining death rates from colorectal cancer (CRC), racial disparities have continued to increase. In this study, the authors examined disparities in a racially diverse group of insured patients.
This study was conducted among patients who were diagnosed with CRC from 1993 to 1998, when they were enrolled in integrated healthcare systems. Patients were identified from tumor registries and were linked to information in administrative databases. The sample was restricted to non-Hispanic whites (n = 10,585), non-Hispanic blacks (n = 1479), Hispanics (n = 985), and Asians/Pacific Islanders (n = 909). Differences in tumor stage and survival were analyzed by using polytomous and Cox regression models, respectively.
In multivariable regression analyses, blacks were more likely than whites to have distant or unstaged tumors. In Cox models that were adjusted for nonmutable factors, blacks had a higher risk of death from CRC (hazard ratio [HR], 1.17; 95% confidence interval [95% CI], 1.06-1.30). Hispanics had a risk of death similar to whites (HR, 1.04; 95% CI, 0.92-1.18), whereas Asians/Pacific Islanders had a lower risk of death from CRC (HR, 0.89; 95% CI, 0.78-1.02). Adjustment for tumor stage decreased the HR to 1.11 for blacks, and the addition of receipt of surgical therapy to the model decreased the HR further to 1.06. The HR among Hispanics and Asians/Pacific Islanders was stable to adjustment for tumor stage and surgical therapy.
The relation between race and survival from CRC was complex and appeared to be related to differences in tumor stage and therapy received, even in insured populations. Targeted interventions to improve the use of effective screening and treatment among vulnerable populations may be needed to eliminate disparities in CRC.

Download full-text


Available from: Eli Korner, Apr 13, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ISPOR Oncology Special Interest Group formed a working group at the end of 2010 to develop standards for conducting oncology health services research using secondary data. The first mission of the group was to develop a checklist focused on issues specific to selection of a sample of oncology patients using a secondary data source. A systematic review of the published literature from 2006 to 2010 was conducted to characterize the use of secondary data sources in oncology and inform the leadership of the working group prior to the construction of the checklist. A draft checklist was subsequently presented to the ISPOR membership in 2011 with subsequent feedback from the larger Oncology Special Interest Group also incorporated into the final checklist. The checklist includes six elements: identification of the cancer to be studied, selection of an appropriate data source, evaluation of the applicability of published algorithms, development of custom algorithms (if needed), validation of the custom algorithm, and reporting and discussions of the ascertainment criteria. The checklist was intended to be applicable to various types of secondary data sources, including cancer registries, claims databases, electronic medical records, and others. This checklist makes two important contributions to oncology health services research. First, it can assist decision makers and reviewers in evaluating the quality of studies using secondary data. Second, it highlights methodological issues to be considered when researchers are constructing a study cohort from a secondary data source.
    Value in Health 06/2013; 16(4):655-669. DOI:10.1016/j.jval.2013.02.006 · 2.89 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With a background of disparities in colorectal cancer (CRC) incidences/mortality across countries due to differences in exposure to various prognostic factors, this study aimed to evaluate the site-specific pattern for the survival of colon and rectal patients. A total of 1,283 patients with CRC diagnosis according to the pathology report of cancer registry of RCGLD from 1 January 2002 to 1 October 2007, were entered into the study. Data were analyzed using univariate and multivariate competing risk survival analysis. Survival proportion of patients showed a significant trend for 1, 3 and 5 year survival in colon cancer (P< 0.001) but this wasn't significant for rectal cancer (P=0.078). Tumor grade and pathologic stage were the most important factors predicting the survival in colon and rectal cancers with stronger hazard in the rectal site for grade and stronger hazard in the colon site for stage. For colon site, in the well and moderate categories of tumor grade, shifting from early to advance stage and also shifting in tumor grade from well and moderate categories to poor tumor grade had a considerable effect in hazard ratios. For rectum site, well to moderate shifting in tumor grade increased the hazard of death and shifting from early to advance stage increased the hazard equal to 2.54 and 4.36 times within the well and moderate tumor differentiation, respectively. In shifting to advance CRC, colon site had generally worse hazard than the rectum. Due to the worse conditions of CRC patients as shifting to advance cancer, to improve the effectiveness of treatment and hence the survival of Iranian patients, we should pay more attention to early detection, in particular by implementing population based screening programmes.
    Asian Pacific journal of cancer prevention: APJCP 01/2011; 12(5):1225-31. · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Integrated healthcare delivery systems present unique opportunities for cancer survivorship research. The National Cancer Institute funds the Cancer Research Network (CRN) to leverage these capabilities for all types of cancer research, including survivorship. The authors gathered information from a recent CRN funding application, Survivorship Interest Group materials, the CRN website, and published articles. CRN studies were selected to illustrate diverse topics and a variety of data-collection approaches. The 14 systems that participate in the CRN provide care for approximately 10.8 million individuals of all ages and racial/ethnic backgrounds, for whom approximately 38,000 new cancer diagnoses were made in 2005. CRN systems have the ability to use existing data and collect new data on patients, providers, and organizations through well established research centers staffed by independent scientists. Of the 45 funded and 2 pending CRN grant applications as of November 30, 2007, 21 include aspects related to cancer survivorship. These studies have examined clinical trial participation, patterns of care, age and racial/ethnic disparities, diffusion of clinical trial findings, treatment outcomes, surveillance, and end-of-life and palliative care. Breast, colorectal, lung, ovarian, and prostate cancers have been the focus of these studies. Results of these studies have been published widely in leading journals. Completed and ongoing CRN survivorship studies provide a strong foundation for future studies. Scientists from all institutional affiliations are welcome to approach the CRN with ideas and are encouraged to allow ample time to establish collaborative relationships and design rigorous studies.
    Cancer 06/2008; 112(11 Suppl):2617-26. DOI:10.1002/cncr.23447 · 4.90 Impact Factor